Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415424 | 1.00 | HCRTR1 (0.54) | HCRTR1HCRTR2MAPK1RORC | |
| SCHEMBL2930753 | 1.00 | HCRTR1 (0.54) | HCRTR1HCRTR2MAPK1RORC | |
| SCHEMBL2930755 | 1.00 | HCRTR1 (0.54) | HCRTR1HCRTR2MAPK1RORC | |
| SCHEMBL496259 | 0.95 | HCRTR1 (0.49) | HCRTR1HCRTR2MAPK1RORC | |
| SCHEMBL2450569 | 0.95 | HCRTR1 (0.49) | HCRTR1HCRTR2MAPK1RORC | |
| SCHEMBL2447646 | 0.91 | HCRTR1 (0.45) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL496234 | 0.91 | HCRTR1 (0.45) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL1398781 | 0.81 | HCRTR1 (0.47) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL983349 | 0.81 | HCRTR1 (0.42) | HCRTR1HCRTR2MAPK1 | |
| SCHEMBL2931770 | 0.81 | HCRTR1 (0.38) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063099-B2 | Trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-22 | — | — | US | disclosed |
| EP-2185512-B1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2185512-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009016560-A2 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204285-A1 | TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885MAPK1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.